DAYS ALIVE OUTSIDE HOSPITAL AND RE-ADMISSIONS IN PATIENTS UNDERGOING ALLOGENEIC TRANSPLANTS FROM IDENTICAL SIBLINGS, UNRELATED DONORS OR HAPLOIDENTICAL DONORS “.

Main Article Content

Federica Sorà
patrizia chiusolo
luca laurenti
idanna innocenti
francesco autore
sabrina giammarco
elisabetta metafuni
eleonora alma
alessia di giovanni
simona sica
andrea bacigalupo
(*) Corresponding Author:

Abstract

We have studied the number of days alive outside Hospital (DAOH) and the number of re-admissions within the first 100 days after transplant in 185 patients who received an allogeneic hemopoietic stem cell transplant (HSCT). The donors were matched siblings (SIB; n=61), or alternative donors (ALT; n=124). The median number of DAOH for SIB transplants (78 days) was significantly greater than DAOH for ALT donor grafts (73 days) (p=0.0003) . Other positive predictors of DAOH were the use of reduced intensity regimens (p=0.01), grade 0-I graft versus host disease (GvHD) (p=0.0006) and a comorbidity index equal or less than two (p=0.04). Fifty one patients required re-admission (22%), which was predicted by grade II-IV GvHD (p=0.009), higher comorbidity index (p=0.06) and ALT donors as compared to SIBS (p=0.08). The CI of re-admission was 18% for SIB and 30% for ALT donor grafts. The non relapse mortality (NRM) for patients re-admitted was 25%, compared to 5% for patients not readmitted (p=0.0001). In a multivariate analysis re-admission was the strongest predictor of non relapse mortality (NRM) (p=0.0006) and survival (p<0.0001).


In conclusions: ALT donor transplants have lower numbers of DAOH, as compared to SIB grafts, which implies longer stay in hospital and greater cost. Re-admission to Hospital within 100 days, is predicted by GvHD, comorbidity index, donor type, and has a very strong impact on non relapse mortality and survival.


Downloads month by month

Downloads

Download data is not yet available.

Article Details

References

References
1. Eapen M, Rocha V, Sanz G et al. Effect of graft source on unrelated donor
haemopoietic stem-cell transplantation in adults with acute leukaemia: a
retrospective analysis. Lancet Oncol. 2010 ;11:653.

2. Marks DI, Woo KA, Zhong X et al. Unrelated umbilical cord blood transplant for
adult acute lymphoblastic leukemia in first and second complete remission: a
comparison with allografts from adult unrelated donors. Haematologica. 2014
;99:322.

3. Ruggeri A, Labopin M, Sanz G et al.Comparison of outcomes after unrelated cord
blood and unmanipulated haploidentical stem cell transplantation in adults with
acute leukemia. Leukemia. 2015 ;299:1891.

4. Robin M, Ruggeri A, Labopin M et al. Comparison of unrelated cord blood and
peripheral blood stem cell transplantation in adults with myelodysplastic syndrome
after reduced-intensity conditioning regimen: a collaborative study from Eurocord
(Cord blood Committee of Cellular Therapy & Immunobiology Working Party of
EBMT) and Chronic Malignancies Working Party. Biol Blood Marrow Transplant.
2015;21:489.

5. Ringdén O, Labopin M, Beelen DW et al. Bone marrow or peripheral blood stem
cell transplantation from unrelated donors in adult patients with acute myeloid
leukaemia, an Acute Leukaemia Working Party analysis in 2262 patients. J Intern
Med. 2012 ;272:472.

6. Nagler A, Labopin M, Shimoni A , et al. Mobilized peripheral blood stem cells
compared with bone marrow as the stem cell source for unrelated donor allogeneic
transplantation with reduced-intensity conditioning in patients with acute myeloid
leukemia in complete remission: an analysis from the Acute Leukemia Working
Party of the European Group for Blood and Marrow Transplantation. Biol Blood
Marrow Transplant. 2012 ;18:1422.

7. Ruggeri A, Ciceri F, Gluckman E et al. Eurocord and Acute Leukemia Working
Party of the European Blood and Marrow Transplant Group.Alternative donors
hematopoietic stem cells transplantation for adults with acute myeloid leukemia:
Umbilical cord blood or haploidentical donors? Best Pract Res Clin Haematol. 2010
;23:207.

8. Khera N, Zeliadt SB, Lee SJ. Economics of hematopoietic cell transplantation.
Blood. 2012;120:1545.

9. Preussler JM, Denzen EM, Majhail NS. Costs and cost-effectiveness of
hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2012; 18:1620.

10. Majhail NS, Mau LW, Denzen EM, et al. Costs of autologous and allogeneic
hematopoietic cell transplantation in the United States: a study using a large
national private claims database. BoneMarrow Transplant. 2013; 48:294.

11. Majhail NS, Mothukuri JM, Brunstein CG, et al. Costs of hematopoietic cell
transplantation:comparison of umbilical cord blood and matched related donor
transplantation and the impact ofposttransplant complications. Biol Blood Marrow
Transplant. 2009; 15:564.

12. Ballen KK, Joffe S, Brazauskas R et al. Hospital length of stay in the first 100 days
after allogeneic hematopoietic cell transplantation for acute leukemia in remission:
comparison among alternative graft sources. Biol Blood Marrow Transplant.
2014;20(11):1819.

13. Ruggeri A, Sun Y, Labopin M et al. Post-transplant cyclophosphamide versus
antithymocyte-globulin as graft versus host disease prophylaxis in haploidentical
transplant. Haematologica 2017 ;102:401.

14. Bacigalupo A, Sica S. HLA Haplotype Mismatch Transplants and Posttransplant
Cyclophosphamide. Adv Hematol. 2016;2016:7802967

15. Finke J, Bethge WA, Schmoor C et al. Standard graft-versus-host disease
prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation
from matched unrelated donors: a randomised, open-label,multicentre phase 3 trial.
Lancet Oncol. 2009 ;9:855.

16. Sorror ML, Storb RF, Sandmaier BM, Maziarz RT, Pulsipher MA, Maris MB et al.
Comorbidity-age index: a clinical measure of biologic age beforen allogeneic
hematopoietic cell transplantation. J Clin Oncol. 2014 :10;:3249.

17. Walker I, Panzarella T, Couban S et al.Pretreatment with anti-thymocyte globulin
versus no anti-thymocyte globulin in patients with haematological malignancies
undergoing haemopoietic cell transplantation from unrelated donors: a randomised,
controlled, open-label, phase 3, multicentre trial. Lancet Oncol. 2016 ;2:164.

18. Fuchs EJ. Related haploidentical donors are a better choice than matched
unrelated donors: Point Blood Advances 2017 1:397.

19. Shaw BE Related haploidentical donors are a better choice than matched unrelated
donors: Counterpoint Blood Advances 2017 1:401.

20. Ringdén O, Labopin M, Ciceri F, et al. Is there a stronger graft-versus-leukemia
effect using HLA-haploidentical donors compared with HLA-identical siblings?
Leukemia. 2016 ;30:447.

21. Bregante S, Dominietto A, Ghiso A et al Improved Outcome of Alternative Donor
Transplantations in Patients with Myelofibrosis: From Unrelated to Haploidentical
Family Donors. Biol Blood Marrow Transplant.2016;22:324.

22. Ciurea SO, Zhang MJ, Bacigalupo AA et al. Haploidentical transplant with
posttransplant cyclophosphamide vs matched unrelated donor transplant for acute
myeloid leukemia. Blood. 2015;126:1033

23. Bacigalupo A, Dominietto A, Ghiso A et al. Unmanipulated haploidentical bone
marrow transplantation and post-transplant cyclophosphamide for hematologic
malignanices following a myeloablative conditioning: an update. Bone Marrow
Transplant. 2015,50 :S37-9

24. Holtick U, Albrecht M, Chemnitz JM et al. Bone marrow versus peripheral blood
allogeneic haematopoietic stem cell transplantation for haematological
malignancies in adults. Cochrane Database Syst Rev. 2014;4:CD010189

25. McCurdy SR, Kasamon YL, Kanakry CG et al. Comparable composite endpoints
after HLA-matched and HLA-haploidentical transplantation with post-transplantation
cyclophosphamide. Haematologica. 2017;102:391.

26. Apperley J, Niederwieser D, Huang XJ et. Reprint of: Haploidentical Hematopoietic
Stem Cell Transplantation: A Global Overview Comparing Asia, the European
Union, and the United States. Biol Blood Marrow Transplant. 2016 ;22:S15-8.

27. De Jong CN, Meijer E, Bakunina C et al. Post transplantation cyclophosphamide after allogeneic hematopoietic stem cell transplantation: results of a prospective randomized HOVON 96 trial in recipient of HLA matched related and unrelated donors. Blood. 2019 ; 134 (suppl.1 ); 1

Most read articles by the same author(s)

1 2 > >>